Investor Webinar – 15 October 2026

AI SummaryClose X

Solvonis Therapeutics plc announced an investor webinar scheduled for October 15, 2026, to discuss its strategy in addiction and mental health therapeutics, focusing on its late clinical-stage small-molecule treatments. The company will provide updates on its alcohol use disorder franchise, including the UK Phase 3 program for SVN-001 and planned European expansion, as well as SVN-002's development for the US market. Additionally, Solvonis will cover its proprietary drug development pipeline, featuring SVN-015 for stimulant use disorder and SVN-114 for post-traumatic stress disorder, highlighting key clinical, regulatory, and commercial milestones.

Disclaimer*

UK 100

Latest directors dealings